NASDAQ:APTX

Aptinyx - APTX Stock Forecast, Price & News

$0.35

-0.01 (-2.75%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.35
▼
$0.40
50-Day Range: $0.35
▼
$0.69
52-Week Range: $0.33
▼
$3.76

Volume: 278,552 shs
Average Volume: 361,526 shs
Market Capitalization: $23.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Aptinyx MarketRank™ Forecast

Analyst Rating: Hold
2.44 Rating Score
Upside/Downside: 747.5% Upside
$3.00 Price Target
Short Interest: Healthy
0.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.02) to ($0.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

175th out of 1,075 stocks

Pharmaceutical Preparations Industry

65th out of 537 stocks

4.2

Analyst's Opinion

Consensus Rating
Aptinyx has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Aptinyx has a forecasted upside of 747.5% from its current price of $0.35.
Amount of Analyst Coverage
Aptinyx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.58% of the float of Aptinyx has been sold short.
Short Interest Ratio / Days to Cover
Aptinyx has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptinyx has recently decreased by 17.84%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aptinyx does not currently pay a dividend.
Dividend Growth
Aptinyx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APTX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Aptinyx this week, compared to 2 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptinyx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.88% of the stock of Aptinyx is held by insiders.
Percentage Held by Institutions
50.62% of the stock of Aptinyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aptinyx are expected to grow in the coming year, from ($1.02) to ($0.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aptinyx is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptinyx is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aptinyx has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptinyx (NASDAQ:APTX) Stock

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Stock News Headlines

October 5, 2022 | americanbankingnews.com

Brokerages Set Aptinyx Inc. (NASDAQ:APTX) Target Price at $2.60

October 2, 2022 | reuters.com

APTX.OQ - Aptinyx Inc | Stock Price & Latest News | Reuters

September 24, 2022 | finance.yahoo.com

Aptinyx Inc. (APTX)

September 12, 2022 | nasdaq.com

Hopeful week for insiders who might be regretting buying US$567k of Aptinyx Inc. (NASDAQ:APTX) stock earlier this year - Nasdaq

August 25, 2022 | businesswire.com

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies - Business Wire

August 25, 2022 | finance.yahoo.com

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

August 22, 2022 | finance.yahoo.com

Bullish Aptinyx Inc. (NASDAQ:APTX) investors are yet to receive a pay off on their US$567k bet

August 19, 2022 | nasdaq.com

Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates - Nasdaq

August 17, 2022 | morningstar.com

North American Morning Briefing: Investors Seek -2- - Morningstar

August 16, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Aptinyx

August 12, 2022 | benzinga.com

Recap Of Friday’s Biotech Catalysts - End Of the Day Summary - Benzinga

August 12, 2022 | marketwatch.com

Aptinyx: Fibromyalgia-Pain Drug Trial Misses Endpoints - MarketWatch

August 12, 2022 | finance.yahoo.com

Aptinyx's Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study

August 12, 2022 | businesswire.com

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia - Business Wire

August 12, 2022 | finance.yahoo.com

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

August 6, 2022 | fool.com

Aptinyx Inc. (APTX) Q2 2022 Earnings Call Transcript - The Motley Fool

August 6, 2022 | fool.com

Aptinyx Inc. (APTX) Q2 2022 Earnings Call Transcript

August 5, 2022 | finance.yahoo.com

Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights - Yahoo Finance

August 4, 2022 | seekingalpha.com

Aptinyx GAAP EPS of -$0.26 beats by $0.02 (NASDAQ:APTX) - Seeking Alpha

August 4, 2022 | businesswire.com

Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights - Business Wire

July 15, 2022 | finance.yahoo.com

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

July 13, 2022 | nasdaq.com

U.S. Silica (SLCA) Wraps Up $100 Million Loan Repurchase - Nasdaq

July 13, 2022 | nasdaq.com

TFII vs. CHRW: Which Stock Should Value Investors Buy Now? - Nasdaq

July 13, 2022 | nasdaq.com

All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy - Nasdaq

July 13, 2022 | nasdaq.com

Philips (PHG) Expands AI Portfolio With SmartSpeed Solution - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Company Calendar

Last Earnings: 8/04/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APTX
CUSIP: N/A
CIK: 1674365
Web: www.aptinyx.com
Phone: (847) 871-0377
Fax: N/A
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +747.5%
Consensus Rating: Hold
Rating Score (0-4): 2.44
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -90.46%
Return on Assets: -70.17%

Debt

Debt-to-Equity Ratio: 0.39
Current Ratio: 16.22
Quick Ratio: 16.22

Sales & Book Value

Annual Sales: $1 million
Price / Sales: 23.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 0.25

Miscellaneous

Outstanding Shares: 67,716,000
Free Float: 61,026,000
Market Cap: $23.97 million
Optionable: Not Optionable
Beta: 1.24

Key Executives

Andrew Kidd
President, Chief Executive Officer & Director

Ashish Khanna
Chief Financial & Business Officer

Sandip K. Agarwala
Board Observer

Kathryn King
Senior Vice President-Clinical & CMC Operations

Patrick Flavin
Head-Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APTX Stock - Frequently Asked Questions

Should I buy or sell Aptinyx stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" APTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APTX, but not buy additional shares or sell existing shares.
View APTX analyst ratings or view top-rated stocks.
What is Aptinyx's stock price forecast for 2022?: 9 Wall Street analysts have issued twelve-month price targets for Aptinyx's shares. Their APTX share price forecasts range from $1.00 to $5.00. On average, they predict the company's share price to reach $3.00 in the next year. This suggests a possible upside of 710.8% from the stock's current price.
View analysts price targets for APTX or view top-rated stocks among Wall Street analysts.
How have APTX shares performed in 2022?: Aptinyx's stock was trading at $2.67 on January 1st, 2022. Since then, APTX stock has decreased by 86.1% and is now trading at $0.37.
View the best growth stocks for 2022 here.
When is Aptinyx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our APTX earnings forecast.
How were Aptinyx's earnings last quarter?: Aptinyx Inc. (NASDAQ:APTX) announced its quarterly earnings data on Thursday, August, 4th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03. During the same quarter last year, the business posted ($0.29) earnings per share.

What other stocks do shareholders of Aptinyx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX).
When did Aptinyx IPO?: (APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
What is Aptinyx's stock symbol?: Aptinyx trades on the NASDAQ under the ticker symbol "APTX."
How do I buy shares of Aptinyx?: Shares of APTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aptinyx's stock price today?: One share of APTX stock can currently be purchased for approximately $0.37.
How much money does Aptinyx make?: Aptinyx (NASDAQ:APTX) has a market capitalization of $25.06 million and generates $1 million in revenue each year. The company earns $-74,890,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact Aptinyx?: Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The official website for the company is www.aptinyx.com. The company can be reached via phone at (847) 871-0377 or via email at investors@aptinyx.com.

This page (NASDAQ:APTX) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aptinyx - APTX Stock Forecast, Price & News

Aptinyx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Aptinyx (NASDAQ:APTX) Stock

APTX Stock News Headlines

APTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

APTX Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™